Clinical Trial Update: An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects [Phase 4]

View source ↗

Summary

Phase 4 open-label, non-randomized single-arm trial to investigate how Nevirapine increases plasma HDL in HIV-infected subjects; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• NEVIRAPINE (nevirapine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections, Metabolism, Lipids | Phase 4 | Status: COMPLETED